Last reviewed · How we verify

NCT00724841

A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma

Terminated Phase 1/Phase 2 Last updated 20 July 2016
What this trial tests

Phase 1/Phase 2 trial testing Obatoclax Mesylate in Metastatic Melanoma in 1 participant. Terminated before completion.

Timeline
1 June 2008
Primary endpoint
1 July 2008
1 August 2010

Quick facts

Lead sponsorGemin X
PhasePhase 1/Phase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment1
Start date1 June 2008
Primary completion1 July 2008
Estimated completion1 August 2010
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Gemin X — full company profile →

Who can join

18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Small Molecule NF-κB Pathway Inhibitors in Clinic.
    Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
  2. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.
    Galli U, Colombo G, Travelli C, Tron GC, et al · · 2020 · cited 122× · PMID 32477131 · DOI 10.3389/fphar.2020.00656
  3. Review of various NAMPT inhibitors for the treatment of cancer.
    Wei Y, Xiang H, Zhang W. · · 2022 · cited 74× · PMID 36160449 · DOI 10.3389/fphar.2022.970553
  4. Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.
    Kaushik V, Yakisich JS, Kumar A, Azad N, et al · · 2018 · cited 58× · PMID 30262730 · DOI 10.3390/cancers10100360
  5. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.
    Mpilla GB, Philip PA, El-Rayes B, Azmi AS. · · 2020 · cited 46× · PMID 32821069 · DOI 10.3748/wjg.v26.i28.4036
  6. NAMPT as a Dedifferentiation-Inducer Gene: NAD<sup>+</sup> as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.
    Lucena-Cacace A, Umeda M, Navas LE, Carnero A. · · 2019 · cited 36× · PMID 31119097 · DOI 10.3389/fonc.2019.00292
  7. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
    Sun X, Turcan S. · · 2021 · cited 31× · PMID 34067729 · DOI 10.3390/cells10051225
  8. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
    Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233

Verify or expand the search:

Other recruiting trials for Metastatic Melanoma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00724841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing